Coherus Biosciences has received FDA approval for an autoinjectable version of its biosimilar Udenyca, which is equivalent to Amgen’s Neulasta, containing pegfilgrastim. The pre-filled syringe formulation of Udenyca will continue to be available after the launch of the autoinjector. The autoinjector will be commercially available in the second quarter of 2023. Denny Lanfear, CEO of Coherus, expressed his company’s commitment to developing innovative solutions that can address the needs of cancer patients, while also expanding access to treatment. The Udenyca autoinjector is the first innovation in the pegfilgrastim space in eight years, according to Lanfear.
Coherus Biosciences has received FDA approval for an autoinjectable version of its biosimilar Udenyca, which is equivalent to Amgen’s Neulasta, containing pegfilgrastim. Udenyca was launched in January 2019 in the US and is one of six pegfilgrastim biosimilars approved by the FDA. It is administered the day after chemotherapy to reduce the likelihood of infection from febrile neutropenia. The pre-filled syringe formulation of Udenyca will continue to be available after the launch of the autoinjector. The autoinjector will be commercially available in the second quarter of 2023. Denny Lanfear, CEO of Coherus, expressed his company’s commitment to developing innovative solutions that can address the needs of cancer patients, while also expanding access to treatment. The Udenyca autoinjector is the first innovation in the pegfilgrastim space in eight years, according to Lanfear.
Don’t miss interesting posts on Famousbio
